Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-01823 · Session 7

What assessment it has made of the impact on patient outcomes of the reported two-year gap in routine access to Oncotype DX testing for nod…

Answered Asked by Jackie Baillie Lab Lodged 20 Jul 2026

The question

To ask the Scottish Government what assessment it has made of the impact on patient outcomes of the reported two-year gap in routine access to Oncotype DX testing for node-positive breast cancer patients in Scotland compared with England and Wales, where NICE guidance was implemented in May 2024.

The answer

Answered by Angela Constance on 4 Aug 2026 · 15 days after it was lodged, on time

Recommendations regarding the use of tumour profiling tests such as Oncotype DX are developed independently of the Scottish Government. The Scottish Health Technologies Group (SHTG) published their recommendation in October 2023, which has been implemented in full. SHTG have criteria and processes in place to judge whether new evidence is sufficient to revise its existing recommendations.

In the Official Report

No contribution in the Official Report cites S7W-01823 by reference.